期刊
PANCREATOLOGY
卷 18, 期 3, 页码 328-333出版社
ELSEVIER
DOI: 10.1016/j.pan.2018.02.006
关键词
Pancreatic cancer; Celecoxib; L1CAM; STAT3/NF-kB
资金
- Development and reform commission of Hunan Province Industry Research Project [2015-99]
- Hunan Province Tumor Hospital Science and Technology Project
Objective: To explore the molecular mechanisms of celecoxib-induced pancreatic cancer suppression in vivo and in vitro. Methods: The anti-pancreatic cancer activities of celecoxib (0, 20, 60 and 100 mmol/L) were investigated by cell viability and migration of Panc-1 and Bxpc-3 cells in vitro. The expression of L1CAM in pancreatic cancer and adjacent tissues was compared using immunohistochemistry. The expressions of L1CAM, STAT3, p-STAT3, NF-kappa B, p-NF-kappa B were determined by western blotting, and cell invasive ability was determined by wound healing assay in L1CAM-silenced and over-expressed Panc-1and Bxpc-3 cells. Results: The expression of L1CAM in pancreatic carcinoma was stronger than that in the adjacent tissues and L1CAM could increase the growth and invasion of pancreatic cancer cells. Over-expression of L1CAM activated the STAT3/NF-kappa B signaling pathway in Panc-1 and Bxpc-3 pancreatic cancer cells and celecoxib inhibited their viability and the expressions of STAT3, p-STAT3, NF-kappa B, p-NF-kappa B as well as full length L1CAM in a concentration dependent manner. Conclusions: L1CAM was highly expressed in pancreatic cancer tissue and positively correlated with age, TNM staging and tumor differentiation. L1CAM activated the STAT/NF-kappa B signaling pathway and celecoxib could inhibit the activity of L1CAM, STAT3 and the NF-kappa B signaling pathway resulting in decreased growth and invasion of pancreatic cancer cells. (C) 2018 Published by Elsevier B.V. on behalf of IAP and EPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据